Lipum AB
LIPUM.ST
| Exchange: | ST |
| Currency | Swedish krone |
| ISIN: | SE0015660899 |
| Primary Ticker: | LIPUM.ST |
| Fiscal Year End: | December |
| Sector: | Healthcare |
| Industry: | Biotechnology |
| Gic Sector: | Health Care |
| Gic Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| Gic Industry: | Biotechnology |
| Gic Sub Industry: | Biotechnology |
| Description: | Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden. |
| Address: | Tvistev Aegen 48C, Umeå, Sweden, 907 36 |
| Website: | https://www.lipum.se |
| Full Time Employees: | 5 |
| Updated On: | 2024-11-09 |
Highlights
| Market Capitalization: | 307579808 |
| Market Capitalization Mln: | 307.57 |
| EBITDA: | -39286000 |
| Wall Street Target Price: | 15 |
| Book Value: | 2.25 |
| Earnings Share: | -2.77 |
| Most Recent Quarter: | 2024-09-30 |
| Operating Margin TTM: | -15.97 |
| Return On Assets TTM: | -0.57 |
| Return On Equity TTM: | -1.26 |
| Revenue TTM: | 53000 |
| Quarterly Revenue Growth YOY: | -0.75 |
| Gross Profit TTM: | -31606000 |
| Diluted Eps TTM: | -2.77 |
Valuation
| Price Sales TTM: | 5803.39 |
| Price Book MRQ: | 6.44 |
| Enterprise Value: | 306485351 |
| Enterprise Value Revenue: | 15437.54 |
| Enterprise Value Ebitda: | -1.48 |
Shares
| Shares Outstanding: | 21212400 |
| Shares Float: | 16145211 |
| Percent Insiders: | 20.59 |
| Percent Institutions: | 18.13 |
Technicals
| Beta: | 0.15 |
| 52 Week High: | 15.2 |
| 52 Week Low: | 5.5 |
| 50 Day MA: | 13.33 |
| 200 Day MA: | 9.61 |
Earnings
| Report Date: | 2024-10-25 |
| Date: | 2024-09-30 |
| Before After Market: | Before Market |
| Currency: | SEK |
| Eps Actual: | -0.07 |
| Report Date: | 2024-06-30 |
| Date: | 2024-06-30 |
| Currency: | SEK |
| Eps Actual: | -1.08 |
| Report Date: | 2024-05-07 |
| Date: | 2024-03-31 |
| Before After Market: | After Market |
| Currency: | SEK |
| Eps Actual: | -0.96 |
| Report Date: | 2024-02-29 |
| Date: | 2023-12-31 |
| Before After Market: | Before Market |
| Currency: | SEK |
| Eps Actual: | -0.97 |
| Report Date: | 2023-10-31 |
| Date: | 2023-09-30 |
| Before After Market: | Before Market |
| Currency: | SEK |
| Eps Actual: | -0.70 |
| Report Date: | 2023-04-25 |
| Date: | 2023-03-31 |
| Before After Market: | After Market |
| Currency: | SEK |
| Eps Actual: | -0.93 |
| Report Date: | 2023-03-24 |
| Date: | 2022-12-31 |
| Before After Market: | After Market |
| Currency: | SEK |
| Eps Actual: | -1.70 |
| Report Date: | 2022-11-25 |
| Date: | 2022-09-30 |
| Before After Market: | Before Market |
| Currency: | SEK |
| Eps Actual: | -1.95 |
| Report Date: | 2022-07-27 |
| Date: | 2022-06-30 |
| Before After Market: | Before Market |
| Currency: | SEK |
| Eps Actual: | -1.84 |
| Report Date: | 2022-05-18 |
| Date: | 2022-03-31 |
| Before After Market: | Before Market |
| Currency: | SEK |
| Eps Actual: | -1.15 |
| Report Date: | 2022-03-25 |
| Date: | 2021-12-31 |
| Currency: | SEK |
| Eps Actual: | -5.77 |
| Report Date: | 2021-09-30 |
| Date: | 2021-09-30 |
| Currency: | SEK |
| Eps Actual: | -1.07 |
| Report Date: | 2021-06-30 |
| Date: | 2021-06-30 |
| Currency: | SEK |
| Eps Actual: | -2.16 |
| Date: | 2024-09-30 |
| Eps Actual: | -2.13 |
| Date: | 2023-12-31 |
| Eps Actual: | -2.62 |
| Date: | 2022-12-31 |
| Eps Actual: | -6.66 |
| Date: | 2021-12-31 |
| Eps Actual: | -9.00 |